<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A53A7F4C-8A8F-4D36-A7B3-2064FB8F1A5C"><gtr:id>A53A7F4C-8A8F-4D36-A7B3-2064FB8F1A5C</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Bartlett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F29623E-E985-4E31-B594-DEBC2CFF4E8B"><gtr:id>3F29623E-E985-4E31-B594-DEBC2CFF4E8B</gtr:id><gtr:firstName>Tracy</gtr:firstName><gtr:surname>Robson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6EE957B5-BA13-402F-AD17-3D56A1DEEB20"><gtr:id>6EE957B5-BA13-402F-AD17-3D56A1DEEB20</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Gallagher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1D0110B4-1EFE-4F47-8047-172C83984EB8"><gtr:id>1D0110B4-1EFE-4F47-8047-172C83984EB8</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001473"><gtr:id>593E9B07-4599-4019-8289-A73CBD56C442</gtr:id><gtr:title>A novel prognostic and predictive marker of resistance to endocrine therapies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001473</gtr:grantReference><gtr:abstractText>Breast cancer is the second biggest cause of death from cancer in the UK, with 3800 women being diagnosed every month. Hormones, in particular oestrogen, are known to promote breast cancer cell growth therefore hormone therapy is one of the main breast cancer treatments. Tamoxifen and aromatase inhibitors are commonly used hormone treatments preventing oestrogen working properly thereby inhibiting cancer growth and improving patient survival rates. Currently patients have their tumour cells tested for the presence of oestrogen and progesterone receptors. Those patients testing positive are treated with tamoxifen or aromatase inhibitors, however almost half of these patients do not respond favourably. It is for this reason that a laboratory test needs to be designed which will predict response to these therapies in patients more accurately. Our previous studies have identified a protein that targets the oestrogen receptor. Tumour cells containing high levels of this protein are more sensitive to tamoxifen and less likely to acquire resistance while tumour cells displaying low levels are resistant to tamoxifen. We aim to develop a diagnostic test so that, before treatment strategies are determined, levels of this protein would be assessed along with oestrogen/progesterone receptor status in tumour samples. Since prompt treatment is vital for cancer survival, this novel test would minimise unnecessary drug treatment and ensure that the most suitable treatment is provided at the earliest possible stage. Our biomarker test appears to be associated with both prognosis as well as response to therapy, making it particularly useful for making decisions regarding treatment.</gtr:abstractText><gtr:technicalSummary>FKBPL is a potential prognostic and/or predictive marker of response to endocrine therapy. High levels slow the growth and sensitize oestrogen receptor positive (ER+ve )breast cancer cells to endocrine therapy, whilst knockdown increases resistance. FKBPL mediates these effects by controlling ER/p21 signaling and stability. Using publically available microarray data, FKBPL correlates with survival in untreated breast cancer patients; with a trend towards significance in tamoxifen treated patients. Using a validated commercially available FKBPL antibody we screened a breast tissue microarray (TMA) cohort, showing FKBPL predicts for recurrence free survival, indicating potential clinical utility. We now aim to fully validate our FKBPL biomarker assay across multiple centres (to ensure reproducibility) and to assess whether TMAs are fully representative of FKBPL expression within tumour sections. We will investigate the use of automated high throughput image analysis for accurate and reproducible quantitative evaluation of this biomarker. The validated assay will then be used to screen multiple TMA cohorts including the 4600 samples from the TEAM trial pathology cohort to validate FKBPL as a predictive/prognostic biomarker. Finally, an extended panel of biomarkers will be used to determine if we can increase sensitivity/specificity in a multi-parameter assay.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-02</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>438699</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Dublin (UCD)</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>MRC funded consortium on FKBPL as a breast cancer biomarker</gtr:description><gtr:id>2B11A619-AA2B-4EBE-8A7C-7163D0748E66</gtr:id><gtr:impact>McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T. (2011) The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans. 39(2):663-8.</gtr:impact><gtr:partnerContribution>Prof Gallagher provides the TMAs</gtr:partnerContribution><gtr:piContribution>We screen TMAs provided by the partner</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit (Belfast)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>46A70703-61E9-45C0-974E-B6CAFBBF367D</gtr:id><gtr:impact>this was a training event for pupils interested in studying medicine. Acted as a facilitator for mock, Multiple Mini Interviews and OSCEs for 60 6th form pupils.

None yet</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stormont visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>84B7015F-ACCF-461D-BC05-3D5C6122A634</gtr:id><gtr:impact>I represented the University at a showcase event at Stormont (NI parliament) . This was a
highly successful University campaign around higher education funding and was intended to showcase the best of the University in
terms of its research, innovation and teaching to MLAs. This was a policy influencing event.

The NI government chose not to increase tuition fees (in NI) after the event.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Soapbox Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FDA272D6-0FF0-44DD-AC5E-213D447B14CC</gtr:id><gtr:impact>Northern Ireland's first Soapboc Science Event. Held in Botanic gardens/Ulster Museum, Belfast. Designed to increase visibility of women in science and was a showcase for QUB research; over 2000 members of the public interacted on the day.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://soapboxscience.org/?page_id=1654</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5095C18A-6AB9-4A66-A83D-ACC7C3E3AC27</gtr:id><gtr:impact>press releaese based on a drug, ALM201, developed in my lab going into a phase I cancer clinical trial in Feb 2014,

This research led to a &amp;pound;13M investment in new Cancer research drug discover initiative to QUB by Invest Northern Ireland, part funded by the European Regional Development Fund and Almac Ltd.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.almacgroup.com/2013/09/almacqueen%E2%80%99s-announce-cancer-research-initiatives-representing-13-million-investment/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television documentary</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B0D0E340-FC64-47B9-92C4-D14A8394F8AC</gtr:id><gtr:impact>'Nolan' television documentary on 'The Truth about Cancer' - BBC1 Northern Irealnd</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b051gfdx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>403432</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phase I/II Clinical Trial for ALM201 for the treatment of solid tumours</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:fundingRef>1303/101195315 - RD0113746</gtr:fundingRef><gtr:id>E9A2384E-2C4E-4F7A-93FA-DDD5878273E5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Almac Sciences</gtr:department><gtr:description>Project grant</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Almac Group</gtr:fundingOrg><gtr:id>5DF5BE77-7EEF-4DE6-A54E-C0CB74ECEA9B</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for Employment and Learning Northern Ireland (DELNI)</gtr:department><gtr:description>Phd Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Government of Northern Ireland</gtr:fundingOrg><gtr:id>7A512064-432D-4282-AA81-A7BBDFD25EE7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant - Confidence in Concept Scheme</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9EAB3D2B-B0BF-47A5-8C34-58E1BE69915F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/I006958/1</gtr:fundingRef><gtr:id>0DDB2929-34EC-4A15-804B-4070CE85B48B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>methods for detecting FKBPL in tumours to prognosticate survival and response to therepay</gtr:description><gtr:id>882C8A03-95BC-41EE-99EC-8A8B4E8E0130</gtr:id><gtr:impact>Assigned to Almac Discovery</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2010133880</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Development of therapeutic ppetides based on FKBPL as anti-angiogenics</gtr:description><gtr:id>83E004C4-59B8-4225-996A-DE9525D82A8E</gtr:id><gtr:impact>Therapeutic peptide ALM201 about to enter phase I clinical trial in ovarian cancer (EudraCT number: 2014-001175-31)</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO/2007/141533</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>FKBP-L AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CTRad -CTRad is an NCRI working group set up to focus on clinical and translational issues relating to radiotherapy, as well as developing a portfolio of practice-changing trials. CTRad has also promotes translation of new discoveries into practice.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F2ECD6BE-5072-4FD4-B047-3EB763D16F91</gtr:id><gtr:impact>Changes in radiotherapy practice</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://ctrad.ncri.org.uk/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ALM201 Phase I Clinical Trial</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>670D094B-AD78-45F8-AD29-A55C49F12E49</gtr:id><gtr:impact>This is a phase I/II clinical trial. In the dose escalation cohort, theer have been no associated toxicities and signs of clinical benefit.</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.hra.nhs.uk/news/research-summaries/phase-1-alm201-in-advanced-ovarian-cancer-and-other-solid-tumours/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>ALM201 has entered a first in man cancer clinical trial in ovarian cancer patients in July 2015. The trial is ongoing</gtr:description><gtr:id>D9F57321-58CC-483A-BDDA-BB9A793E8CC6</gtr:id><gtr:impact>Too early- no adverse toxicity at MTD and signs of disease stabilisation in some patients</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ALM201</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.hra.nhs.uk/news/research-summaries/phase-1-alm201-in-advanced-ovarian-cancer-and-other-solid-tumours/</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The IP has now been assigned to Almac Discovery</gtr:description><gtr:id>DA86C331-C2CB-4784-881F-3DCA6F9DA8C5</gtr:id><gtr:impact>We have now shown in a 3200 patient cohort that FKBPL is prognostic and predictive of response to tamoxifen in breast cancer patients. We hope that this will be further validated in larger studies.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title> ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25906750</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a 'fit for purpose' cancer biomarker assay based on detecting the levels of FKBPL in tumours that helps prognosticate on patient survival and predicts response to endocrine therapy</gtr:description><gtr:id>69B9F5F1-E09A-43E7-8EE9-5C80FF5A43F7</gtr:id><gtr:impact>None yet</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>FKBPL biomarker assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25906750</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDA7FF71-F3F1-4896-88EF-B65E8D9890FE"><gtr:id>EDA7FF71-F3F1-4896-88EF-B65E8D9890FE</gtr:id><gtr:title>Recent Research Developments in Endocrinology, Vol. 5</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45c5c2b8d1692da6091d004029d5db53"><gtr:id>45c5c2b8d1692da6091d004029d5db53</gtr:id><gtr:otherNames>A. Yakkundi, T. Robson and H.D. McKeen</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-81-7895-567-4</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/421961E1-9B8D-461B-BD0D-78E75492964F"><gtr:id>421961E1-9B8D-461B-BD0D-78E75492964F</gtr:id><gtr:title>The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d38936289bec2e199d5d8b3fa6cfb7b7"><gtr:id>d38936289bec2e199d5d8b3fa6cfb7b7</gtr:id><gtr:otherNames>Robson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D57D59A-C959-487A-8C03-159587C70D40"><gtr:id>3D57D59A-C959-487A-8C03-159587C70D40</gtr:id><gtr:title>The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a017796c5efaa31bcd2d8d6bb498f397"><gtr:id>a017796c5efaa31bcd2d8d6bb498f397</gtr:id><gtr:otherNames>Yakkundi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E45DE7E-F1C5-4F7E-B974-1F0F71C18903"><gtr:id>0E45DE7E-F1C5-4F7E-B974-1F0F71C18903</gtr:id><gtr:title>Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b01ec180b0c30284d14d051dd97d46e8"><gtr:id>b01ec180b0c30284d14d051dd97d46e8</gtr:id><gtr:otherNames>Donley C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B542FCC2-D923-4DAF-966F-DD12E4342D4B"><gtr:id>B542FCC2-D923-4DAF-966F-DD12E4342D4B</gtr:id><gtr:title>The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/244c1b7e8391220a156836a146be7dd0"><gtr:id>244c1b7e8391220a156836a146be7dd0</gtr:id><gtr:otherNames>McKeen HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E3057A2-9FAD-4F12-B11C-2BA1A2F071BE"><gtr:id>6E3057A2-9FAD-4F12-B11C-2BA1A2F071BE</gtr:id><gtr:title>Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6102ec8bfcb4cfb87cb034e8c4067870"><gtr:id>6102ec8bfcb4cfb87cb034e8c4067870</gtr:id><gtr:otherNames>Lawler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/807DBE47-E15B-4F92-B9E3-62ECAE5ED5C5"><gtr:id>807DBE47-E15B-4F92-B9E3-62ECAE5ED5C5</gtr:id><gtr:title>FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/244c1b7e8391220a156836a146be7dd0"><gtr:id>244c1b7e8391220a156836a146be7dd0</gtr:id><gtr:otherNames>McKeen HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/422DB9DF-DE1F-4DB1-805F-2FBD5B922BAB"><gtr:id>422DB9DF-DE1F-4DB1-805F-2FBD5B922BAB</gtr:id><gtr:title>Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dd565789662d77d1b41e54beb25169e"><gtr:id>3dd565789662d77d1b41e54beb25169e</gtr:id><gtr:otherNames>McClements L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001473</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>